Navigation Links
EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting

isorder (MDD). The trial is designed to evaluate the effect of treatment with up to 120 mg of PRX-00023 twice-daily for eight weeks as determined by change from baseline in MADRS compared with placebo. Data from this trial are expected in the first half of 2008.

About PRX-00023

PRX-00023 is a novel, highly selective, once-daily, 5-HT1A partial agonist discovered using the company's proprietary G-Protein Coupled Receptors (GPCR) modeling, screening and lead optimization technology. PRX-00023 is targeting a significant unmet medical need and commercial opportunity for a selective, once-daily, 5-HT1A agonist used in the treatment of depression that avoids the sexual dysfunction, withdrawal symptoms and sleep disturbances typically associated with selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs), lacks the addictive and sedative effects of the benzodiazepines, and does not have the slow onset, short half-life, and side effects of a chemical class of 5-HT1A agonists called azapirones. PRX-00023 is the subject of a composition of matter patent held by EPIX which extends through 2024.

About EPIX

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, PRX-03140 which is in a Phase 2a clinical trial in Alzheimer's disease, PRX-00023 which is in Phase 2b clinical development to treat major depression, and PRX-07034, which recently completed a Phase 1b trial and is in cli
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
(Date:8/30/2014)... 2014 According to Bloomberg , ... requires Takeda Pharmaceutical Co. and Eli Lilly & Co. ... that the drugmakers concealed information about a risk of ... case, Allen v. Takeda Pharmaceuticals North America Inc. (12-cv-00064), ... of Louisiana (Lafayette).* , According to Bloomberg, Takeda and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
(Date:8/30/2014)... Plains, NJ (PRWEB) August 30, 2014 ... first facilities in New Jersey and even in the ... technology that takes inches off of patients’ waists with ... freezing cells in small sections, Vanquish is more inclusive ... pain. Patients lay comfortably under panels about one ...
(Date:8/30/2014)... Jackson, Tenn. (PRWEB) August 30, 2014 ... people around the country for the past several ... the Tennessee Hyperbaric Center have announced a scholarship ... PTSD. This announcement follows a meeting held this ... , In recent years, reporters have shed light ...
(Date:8/30/2014)... Insomnia causes disturbances in every aspect of life. ... developed insomnia and the steps often used to return back ... to the show at this link: Dr. Carol Francis ... 30, and will be podcasted at this link (Click ... DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. Weight ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2
... and Mehmet Oz, MD, Launch Daily Syndicated ... Newspaper Column, ... E? Who better to keep the health momentum going than the YOU ... expert for The Oprah Winfrey Show. King Features Syndicate and,RealAge.com announce the ...
... Texas University of Texas Medical Branch at Galveston ... weapon against respiratory syncytial virus, the most common cause ... an effort to find an effective antiviral therapy for ... molecule to interfere with the genetic machinery that RSV ...
... Response Essentially Met but Donations Still Needed to Prepare,for ... WASHINGTON, May 5 The American Red Cross,today ... the Southeastern,Virginia tornadoes but donations to its Disaster Relief ... the next disaster, particularly with the,beginning of hurricane season ...
... Exclusive License for Pulse!! Virtual Learning Platform for ... Clinical Skills and Decision Making Training, ... developer of,game-based technology solutions for training, experimentation and,decision-making analysis, ... System for the exclusive, worldwide rights to Pulse!! the,Virtual ...
... Herley Industries, Inc.,(Nasdaq: HRLY ) announced today ... U.S. Government on all existing criminal and civil,claims. These ... had been scheduled for trial on May 5, 2008 ... control oscillators in January 2001 and,two contracts involving the ...
... a previously unrealized mechanism by which the epidermal growth ... cancer cells through a kinase-independent mechanism. The research, published ... journal Cancer Cell, provides a rationale for the less ... at interfering with kinase activity and suggests new directions ...
Cached Medicine News:Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 2Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 3Health News:New agent strikes at respiratory syncytial virus replication 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 3Health News:Game-Based Technology to Meet Demand for Improved Medical Teaching and Training 2Health News:Game-Based Technology to Meet Demand for Improved Medical Teaching and Training 3Health News:Herley Announces Settlement Agreement with U.S. Government 2Health News:Herley Announces Settlement Agreement with U.S. Government 3Health News:EGFR protects cancer cells from starvation via a kinase-independent mechanism 2
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... series facilitates fast and effective resection of ... shaped meniscal rim. The flat, crescent-shaped tip ... even the tightest joint spaces. Made in ... years of engineering experience in arthroscopy hand ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
Medicine Products: